U.S. markets closed
  • S&P 500

    3,811.15
    -18.19 (-0.48%)
     
  • Dow 30

    30,932.37
    -469.64 (-1.50%)
     
  • Nasdaq

    13,192.35
    +72.92 (+0.56%)
     
  • Russell 2000

    2,201.05
    +0.88 (+0.04%)
     
  • Crude Oil

    61.66
    -1.87 (-2.94%)
     
  • Gold

    1,733.00
    -42.40 (-2.39%)
     
  • Silver

    26.70
    -0.98 (-3.56%)
     
  • EUR/USD

    1.2088
    -0.0099 (-0.81%)
     
  • 10-Yr Bond

    1.4600
    -0.0580 (-3.82%)
     
  • GBP/USD

    1.3922
    -0.0091 (-0.65%)
     
  • USD/JPY

    106.5500
    +0.3200 (+0.30%)
     
  • BTC-USD

    44,648.11
    -3,019.84 (-6.34%)
     
  • CMC Crypto 200

    912.88
    -20.25 (-2.17%)
     
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • Nikkei 225

    28,966.01
    -1,202.26 (-3.99%)
     

Medtronic (MDT) Carpediem to Tap Pediatric Kidney Care Market

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Medtronic plc MDT recently made the commercial launch of its cardio-renal pediatric dialysis emergency machine, Carpediem. In April, the FDA granted marketing authorization for this device targeted to provide continuous hemodialysis or hemofiltration therapy to critically ill pediatric patients weighing between 2.5 and 10 kilograms or 5.5 to 22 pounds.

At Cincinnati Children's Hospital Medical Center, the first Carpediem system has been successfully installed.

Carpediem System at a Glance

The continuous hemodialysis or hemofiltration therapy is also known as continuous renal replacement therapy (CRRT). This system, implemented in ICU settings, uses dialysis machine and a special filter called dialyzer to clean a patient’s blood for an extended period of time, without any halt. This compares with the traditional three times a week therapy session.

Carpediem CRRT system is the first device for a lower weight-specific pediatric patient population. This system targets critically ill patients with high risk of acute kidney injury and fluid overload requiring hemodialysis or hemofiltration therapy.

Kidney Care Prospect in the Pediatric Market

At present, there are lucrative opportunities in pediatric dialysis market. Approximately 10,000 children develop acute kidney injury in the United States each year. According to Medtronic, children on its therapy have a survival rate of only 38-43%. The mortality rate for neonates with acute kidney injury has been reported to be as high as 60%.

Carpediem – a Strategic Inclusion

The existing CRRT devices available in the United States are intended for use in patients weighing at least 20 kilograms and are not approved for use in pediatric patients weighing between 2.5 and 10 kilograms. The CARPEDIEM System accordingly is expected to successfully address the untapped market of pediatric patients between 2.5 and 10 kilograms.

Price Performance

Over the past six months, Medtronic has outperformed the industry it belongs to. The stock has risen 14% compared with the industry's 8% rise.

Zacks Rank & Key Picks

Currently, Medtronic carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Hologic, Inc. HOLX, Thermo Fisher Scientific Inc. TMO and ResMed Inc. RMD.

Hologic’s long-term earnings growth rate is estimated at 17.4%. The company presently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Thermo Fisher’s long-term earnings growth rate is estimated at 18%. It currently carries a Zacks Rank #2 (Buy).

ResMed’s long-term earnings growth rate is estimated at 14.5%. The company presently carries a Zacks Rank #2.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don’t buy now, you may kick yourself in 2021.

Click here for the 6 trades >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Medtronic PLC (MDT) : Free Stock Analysis Report
 
Hologic, Inc. (HOLX) : Free Stock Analysis Report
 
ResMed Inc. (RMD) : Free Stock Analysis Report
 
Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.